Developing a Method to Objectively Measure Opioid Analgesia

Description

Inappropriate prescribing is the fundamental upstream driver of the opioid epidemic. Objective measures to determine the appropriateness of an opioid intervention, provide monitoring of the therapy for adequacy of dose and detection of tolerance or hyperalgesia would eliminate the subjective nature of opioid mediated pain management and obviate iatrogenic facilitation of opioid abuse. The present study is designed to objectively determine whether our device can pain type and determine analgesic efficacy thereby optimizing treatment selection and opioid management.

Conditions

Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use

Study Overview

Study Details

Study overview

Inappropriate prescribing is the fundamental upstream driver of the opioid epidemic. Objective measures to determine the appropriateness of an opioid intervention, provide monitoring of the therapy for adequacy of dose and detection of tolerance or hyperalgesia would eliminate the subjective nature of opioid mediated pain management and obviate iatrogenic facilitation of opioid abuse. The present study is designed to objectively determine whether our device can pain type and determine analgesic efficacy thereby optimizing treatment selection and opioid management.

Developing a Method to Objectively Measure Opioid Analgesia: A Pilot Study

Developing a Method to Objectively Measure Opioid Analgesia

Condition
Analgesics, Antipyretics and Anti-Inflammatory Drugs Causing Adverse Effects in Therapeutic Use
Intervention / Treatment

-

Contacts and Locations

Washington

Children's National Health System, Washington, District of Columbia, United States, 20010

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. The subject is 7 to 21 years of age
  • 2. The subject is receiving an opioid via bolus or a patient controlled analgesia (PCA) apparatus as part of treatment or fentanyl infusion in the pediatric intensive care unit (PICU) (generally postoperative patients).
  • 3. The subject is willing and able to provide written informed assent/parental consent to study participation
  • 1. Eye pathology precluding pupillometry
  • 2. For patients in the PICU, patients who are hemodynamically unstable

Ages Eligible for Study

7 Years to 21 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Julia Finkel,

Julia C Finkel, MD, PRINCIPAL_INVESTIGATOR, Children's National Health System

Study Record Dates

2024-12-01